GSK plcGSKNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.81% | +2.08% | +1.29% | +6.68% | +4.79% |
| Gross Profit Growth | -1.35% | +3.45% | +1.02% | +12.00% | +6.18% |
| EBITDA Growth | -3.28% | +49.42% | +39.95% | +187.02% | +73.24% |
| Operating Income Growth | +21.47% | +48.72% | +22.90% | +1271.96% | +36.85% |
| Net Income Growth | +18.29% | +55.26% | +23.02% | +0.00% | +51.62% |
| EPS Growth | +17.65% | +53.85% | +24.14% | +0.00% | +60.00% |
| EPS Diluted Growth | +17.65% | +56.00% | +25.00% | +0.00% | +50.00% |
| Weighted Average Shares Growth | +0.61% | +0.47% | -0.39% | -1.13% | -1.52% |
| Weighted Average Shares Diluted Growth | +0.66% | +0.58% | -0.29% | +0.54% | -1.42% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -35.64% | -3.83% | +88.32% | +40.56% | -12.57% |
| Free Cash Flow Growth | -60.61% | -20.45% | +118.03% | +98.11% | +23.63% |
| Receivables Growth | -36.43% | +5.12% | +7.28% | +51.42% | +29.11% |
| Inventory Growth | -19.12% | +7.52% | +12.35% | +39.17% | +4.31% |
| Asset Growth | -20.95% | +6.01% | +10.63% | +42.26% | +2.60% |
| Book Value per Share Growth | -20.14% | +4.03% | +12.00% | +56.96% | +21.43% |
| Debt Growth | -26.05% | +5.97% | +11.03% | +48.80% | +4.14% |
| R&D Expense Growth | -0.78% | +1.95% | +37.03% | +15.76% | +13.72% |
| SG&A Expenses Growth | -0.56% | -0.81% | -13.18% | -41.08% | -0.89% |